Bone Biologics Corporation
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. Its NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. The company is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. Its platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -0.43 | $0 | -$804,280 |
| 2025 Q4 | -0.63 | $0 | -$714,762 |
| 2025 Q3 | -0.37 | $0 | -$591,384 |
| 2025 Q2 | -1.33 | $0 | -$458,879 |
| 2025 Q1 | -0.32 | $0 | -$926,120 |
| 2024 Q4 | -0.48 | $0 | -$1M |
| 2024 Q3 | -2.37 | $0 | -$572,162 |
| 2024 Q2 | -0.67 | $0 | -$895,865 |